Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Equity Ratio (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Equity Ratio readings, the most recent being 0.42 for Q4 2023.

  • On a quarterly basis, Equity Ratio rose 109.3% to 0.42 in Q4 2023 year-over-year; TTM through Dec 2023 was 0.42, a 109.3% increase, with the full-year FY2023 number at 0.42, up 109.3% from a year prior.
  • Equity Ratio hit 0.42 in Q4 2023 for Elicio Therapeutics, down from 0.43 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.66 in Q1 2021 to a low of 4.51 in Q4 2022.
  • Median Equity Ratio over the past 4 years was 0.77 (2021), compared with a mean of 0.79.
  • Biggest five-year swings in Equity Ratio: crashed 483.58% in 2022 and later surged 150.04% in 2023.
  • Elicio Therapeutics' Equity Ratio stood at 1.91 in 2020, then skyrocketed by 59.57% to 0.77 in 2021, then crashed by 483.58% to 4.51 in 2022, then surged by 109.3% to 0.42 in 2023.
  • The last three reported values for Equity Ratio were 0.42 (Q4 2023), 0.43 (Q3 2023), and 0.63 (Q2 2023) per Business Quant data.